Abstract: Compounds of formula I: ##STR1## wherein: R1 is hydrogen or alkyl;R2 is alkyl optionally substituted by one or more alkoxy groups or halogen atoms;X is a group of formula --OR3 wherein R3 is alkyl, cycloalkyl, or arylalkyl; or X is a group of formula --NHCVR4 wherein V is oxygen or sulphur, R4 is hydrogen, alkyl, cycloalkyl (which alkyl and cycloalkyl groups may be substituted), alkenyl, aryl, arylalkyl, amino, mono- or di-alkylamino or a group of the formula --OR5 wherein R5 is optionally substituted alkyl, aryl or arylalkyl; or X is a group of formula --NHSO.sub.2 R4a wherein R4a is alkyl, aryl or a group of formula --CH.sub.2 COR4b wherein R4b is alkyl or aryl;Y is optionally substituted alkoxy, cycloalkoxy, arylalkoxy or a group of formula --NR6R7 wherein R6 is hydrogen or alkyl and R7 is alkyl, cycloalkyl (which alkyl and cycloalkyl groups may be substituted), aryl or arylalkyl or R7 is a group of formula --COOR8 wherein R8 is alkyl are useful intermediates in the synthesis of beta-lactam antibiotics.

Abstract: Compounds of formula I: ##STR1## wherein: R1 is hydrogen or alkyl;R2 is alkyl optionally substituted by one or more alkoxy groups or halogen atoms;X is a group of formula --OR3 wherein R3 is alkyl, cycloalkyl, or arylalkyl; or X is a group of formula --NHCVR4 wherein V is oxygen or sulphur, R4 is hydrogen, alkyl, cycloalkyl (which alkyl and cycloalkyl groups may be substituted), alkenyl, aryl, arylalkyl, amino, mono- or di-alkylamino or a group of the formula --OR5 wherein R5 is optionally substituted alkyl, aryl or arylalkyl; or X is a group of formula --NHSO.sub.2 R4a wherein R4a is alkyl, aryl or a group of formula --CH.sub.2 COR4b wherein R4b is alkyl or aryl;Y is optionally substituted alkoxy, cycloalkoxy, arylalkoxy or a group of formula --NR6R7 wherein R6 is hydrogen or alkyl and R7 is alkyl, cycloalkyl (which alkyl and cycloalkyl groups may be substituted), aryl or arylalkyl or R7 is a group of formula --COOR8 wherein R8 is alkyl are useful intermediates in the synthesis of beta-lactam antibiotics.

Abstract: 1,3-Diazolyl-2-propanol derivatives of the formula ##STR1## wherein X and Y are N or CH, R.sup.1 is phenyl, heterocyclyl, heterocyclyl-alkyl, -alkenyl or -alkynyl, optionally substituted, R.sup.2 and R.sup.3 are hydrogen or alkyl, and R.sup.4 and R.sup.5 are hydrogen, amino, alkoxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, or alkenyl, or phenyl, phenylalkyl or phenylalkenyl, heterocycyl, heterocyclyalkyl or heterocyclylalkenyl, each optionally substituted, provided that when R.sup.1 is optionally substituted phenyl at least one of R.sup.1, R.sup.4 and R5 is, or contains, a phenyl ring bearing at least one substitutent selected from cyano, cyanoalkyl, nitro, aminocarbonylalkyl, halogeneoalkoxy and radicals of the formulae --CONR.sup.6 R.sup.7, --NHCOR.sup.8 or OR.sup.

Abstract: The disclosure relates to novel 3,4-disubstituted-branched-chain-acylanilides, processes for their manufacture and pharmaceutical compositions containing them. The compounds possess anti-androgenic activity. Representative of the compounds disclosed is 3,4-dicyanoisobutyranilide.

Abstract: The disclosure relates to novel 3,4-disubstituted-branched-chain-acylanilides, processes for their manufacture and pharmaceutical compositions containing them. The compounds possess anti-androgenic activity. Representative of the compounds disclosed is 3,4-dicyanoisobutyranilide.